Transformational merger brings together Telix’s commercial precision medicine platform with ITM’s scaled radioisotope ...

Women in Singapore now have another option to support their cervical health following Human Papillomavirus (HPV) infection, ...

Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final ...

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease ...

Expanded Unique Dual Index range enables high-throughput laboratories to quadruple multiplexing capacity while retaining ...

US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its ...

Twenty-six figures, each cited to a primary disclosure with its date attached, that together tell the Asia-Pacific biopharma year: where the capital concentrated, what the deals validated, how a ...

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises that the Therapeutic Goods Administration (TGA) ...

MHLW authorisation, supported by Phase III SUNRISE and SUNSET studies, clears the way for Lundbeck’s first independent product launch in Japan. Eptinezumab is the only intravenous (IV) CGRP-targeted ...

The development of HCAbLM marks an important advancement in Nona's application of artificial intelligence (AI) to antibody discovery and development. By combining large-scale antibody repertoires with ...

Korea's health ministry estimates that between 10,000 and 20,000 of its citizens travel abroad every year for stem cell treatment. Fourteen months after the country legalised a domestic route, exactly ...

Preliminary MAGMAP trial results in 62 patients show a 96% sentinel node identification rate and no false negatives in the ...